Viking Therapeutics, Inc. (VKTX) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 509.32M USD | Research and Development Expense |
| Revenue | 0.00 USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 37.39M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -560.02M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $509.32M | $0.00 | $37.39M | $-560.02M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $453.71M | $0.00 | $39.81M | $-502.00M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $344.95M | $0.00 | $40.82M | $-393.34M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $222.48M | $0.00 | $37.90M | $-274.84M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $155.31M | $0.00 | $39.54M | $-212.84M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $118.93M | $0.00 | $33.08M | $-172.32M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $101.64M | $0.00 | $29.71M | $-150.92M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $91.16M | $0.00 | $28.13M | $-133.97M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $86.75M | $0.00 | $23.62M | $-124.68M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $76.90M | $0.00 | $21.16M | $-114.36M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $63.81M | $0.00 | $16.75M | $-100.83M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $59.48M | $0.00 | $14.83M | $-91.83M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $53.06M | $0.00 | $12.29M | $-80.76M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $52.69M | $0.00 | $9.88M | $-74.65M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $54.23M | $0.00 | $8.67M | $-70.36M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $47.90M | $0.00 | $7.95M | $-62.58M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $46.74M | $0.00 | $7.61M | $-59.79M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $46.00M | $0.00 | $6.88M | $-57.70M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $44.98M | $0.00 | $6.10M | $-55.68M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $44.18M | $0.00 | $5.71M | $-54.44M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $40.51M | $0.00 | $5.58M | $-50.88M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $35.48M | $0.00 | $5.74M | $-45.94M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $31.93M | $0.00 | $5.82M | $-42.66M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $29.33M | $0.00 | $5.75M | $-40.27M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $27.50M | $0.00 | $5.09M | $-37.87M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $27.05M | $0.00 | $4.36M | $-36.83M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $23.56M | $0.00 | $3.74M | $-32.69M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $22.20M | $0.00 | $3.38M | $-30.85M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $22.60M | $0.00 | $3.32M | $-30.81M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $20.49M | $0.00 | $3.03M | $-28.16M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $19.04M | $0.00 | $2.61M | $-26.16M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $16.98M | $0.00 | $2.35M | $-23.55M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $14.76M | $0.00 | $1.95M | $-20.85M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $13.26M | $0.00 | $1.66M | $-18.91M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $13.74M | $0.00 | $1.45M | $-19.07M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $13.36M | $0.00 | $1.45M | $-18.38M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $12.00M | $0.00 | $1.42M | $-16.95M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $10.65M | $0.00 | $1.57M | $-15.55M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $9.00M | $0.00 | $1.79M | $-13.85M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $9.57M | $0.00 | $1.96M | $-14.73M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $9.98M | $0.00 | $2.24M | $-15.75M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $8.71M | $0.00 | $3.23M | $-14.80M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $6.97M | $0.00 | $2.60M | $-12.00M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $22.22M | $0.00 | $6.26K | $-23.47M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |